Cargando…
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12
AIM: To gather data on the antiviral efficacy and safety of second generation direct acting antiviral (DAA) treatment with respect to sustained virological response (SVR) 12 wk after conclusion of treatment, and to determine predictors of SVR12 in this setting. METHODS: Two hundred and sixty patient...
Autores principales: | Werner, Christoph R, Schwarz, Julia M, Egetemeyr, Daniel P, Beck, Robert, Malek, Nisar P, Lauer, Ulrich M, Berg, Christoph P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028818/ https://www.ncbi.nlm.nih.gov/pubmed/27672299 http://dx.doi.org/10.3748/wjg.v22.i35.8050 |
Ejemplares similares
-
First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort
por: Werner, Christoph R, et al.
Publicado: (2015) -
Feasibility of Telaprevir-Based Triple Therapy in Liver Transplant Patients with Hepatitis C Virus: SVR 24 Results
por: Werner, Christoph R., et al.
Publicado: (2013) -
Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals
por: Lin, Chuan-Pin, et al.
Publicado: (2021) -
Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil
por: Lourenço, Mariana Sandoval, et al.
Publicado: (2022) -
SVR achievement in triple therapy treated hepatitis C induced cirrhosis: A dual center retrospective cohort study
por: Sheikh, Naukhaiz Taqi, et al.
Publicado: (2022)